智通财经网·2025-12-10 01:37Group 1 - Fosun Pharma (02196) opened over 4% higher, currently up 4.19% at HKD 22.38, with a trading volume of HKD 8.5715 million [1] - The company announced a licensing agreement with Pfizer on December 9, 2025, allowing Pfizer exclusive rights to develop, use, produce, and commercialize the oral small molecule GLP-1 receptor agonist (including YP05002) globally for all human and animal indications [1] - Under this agreement, Fosun Pharma's subsidiary, YaoYao Pharmaceutical, will receive an upfront payment of USD 150 million and up to USD 350 million in milestone payments based on the clinical and commercialization progress of the licensed product [1] Group 2 - YP05002 is an oral small molecule GLP-1 receptor agonist developed by the company, designed to treat type 2 diabetes, obesity, and related diseases by promoting insulin secretion and reducing glucagon secretion [2] - The potential indications for YP05002 include long-term weight management, type 2 diabetes, and metabolic dysfunction-related fatty liver disease (non-alcoholic steatohepatitis) [2] - As of December 9, 2025, YP05002 is in Phase I clinical trials in Australia [2]